{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:04:19Z","timestamp":1792109059658,"version":"4.4.0"},"reference-count":49,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"unspecified","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,4,4]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We conducted an updated systematic review and meta-analysis to investigate the effect of colchicine treatment on clinical outcomes in patients with COVID-19.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Systematic review and meta-analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data sources<\/jats:title>\n                  <jats:p>We searched PubMed, Embase, the Cochrane Library, medRxiv and ClinicalTrials.gov from inception to January 2023.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Eligibility criteria<\/jats:title>\n                  <jats:p>All randomised controlled trials (RCTs) that investigated the efficacy of colchicine treatment in patients with COVID-19 as compared with placebo or standard of care were included. There were no language restrictions. Studies that used colchicine prophylactically were excluded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data extraction and synthesis<\/jats:title>\n                  <jats:p>We extracted all information relating to the study characteristics, such as author names, location, study population, details of intervention and comparator groups, and our outcomes of interest. We conducted our meta-analysis by using RevMan V.5.4 with risk ratio (RR) and mean difference as the effect measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 23 RCTs (28\u2009249 participants) in this systematic review. Colchicine did not decrease the risk of mortality (RR 0.99; 95%\u2009CI 0.93 to 1.05; I<jats:sup>2<\/jats:sup>=0%; 20 RCTs, 25\u2009824 participants), with the results being consistent among both hospitalised and non-hospitalised patients. There were no significant differences between the colchicine and control groups in other relevant clinical outcomes, including the incidence of mechanical ventilation (RR 0.75; 95%\u2009CI 0.48 to 1.18; p=0.22; I<jats:sup>2<\/jats:sup>=40%; 8 RCTs, 13\u2009262 participants), intensive care unit admission (RR 0.77; 95%\u2009CI 0.49 to 1.22; p=0.27; I<jats:sup>2<\/jats:sup>=0%; 6 RCTs, 961 participants) and hospital admission (RR 0.74; 95%\u2009CI 0.48 to 1.16; p=0.19; I<jats:sup>2<\/jats:sup>=70%; 3 RCTs, 8572 participants).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results of this meta-analysis do not support the use of colchicine as a treatment for reducing the risk of mortality or improving other relevant clinical outcomes in patients with COVID-19. However, RCTs investigating early treatment with colchicine (within 5\u2009days of symptom onset or in patients with early-stage disease) are needed to fully elucidate the potential benefits of colchicine in this patient population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42022369850.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-074373","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T12:50:44Z","timestamp":1713358244000},"page":"e074373","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Colchicine for the treatment of patients with COVID-19: an updated systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-7137","authenticated-orcid":false,"given":"Huzaifa Ahmad","family":"Cheema","sequence":"first","affiliation":[{"name":"Department of Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzair","family":"Jafar","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abia","family":"Shahid","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waniyah","family":"Masood","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Usman","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa Hamza","family":"Hermis","sequence":"additional","affiliation":[{"name":"Nursing College, Al-Mustaqbal University, 51001 Hillah, Babylon, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Arsal","family":"Naseem","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda","family":"Sahra","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Sah","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune 411018, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5577-0940","authenticated-orcid":false,"given":"Ka Yiu","family":"Lee","sequence":"additional","affiliation":[{"name":"Swedish Winter Sports Research Centre, Department of Health Sciences, Mid Sweden University, Sundsvall, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"2025101811465972000_14.4.e074373.1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for COVID-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"2025101811465972000_14.4.e074373.2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejim.2022.05.024","article-title":"Efficacy and safety of Molnupiravir for COVID-19 patients","volume":"102","author":"Fatima","year":"2022","journal-title":"Eur J Intern Med"},{"key":"2025101811465972000_14.4.e074373.3","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28471","article-title":"Nirmatrelvir\u2013Ritonavir for the treatment of COVID\u201019 patients: a systematic review and meta\u2010analysis","volume":"95","author":"Cheema","year":"2023","journal-title":"J Med Virol"},{"key":"2025101811465972000_14.4.e074373.4","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/17512433.2023.2267973","article-title":"Nirmatrelvir\/Ritonavir and Molnupiravir: an update on COVID-19 Antivirals in the Omicron era","volume":"16","author":"Faraz","year":"2023","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"2025101811465972000_14.4.e074373.5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jinf.2022.10.012","article-title":"Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: a systematic review and meta-analysis","volume":"85","author":"Cheema","year":"2022","journal-title":"J Infect"},{"key":"2025101811465972000_14.4.e074373.6","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/ptr.7724","article-title":"Curcumin for the treatment of COVID\u201019 patients: a meta\u2010analysis of randomized controlled trials","volume":"37","author":"Shafiee","year":"2023","journal-title":"Phytotherapy Research"},{"key":"2025101811465972000_14.4.e074373.7","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2427","article-title":"Quercetin for the treatment of COVID\u201019 patients: a systematic review and meta\u2010analysis","volume":"33","author":"Cheema","year":"2023","journal-title":"Rev Med Virol"},{"key":"2025101811465972000_14.4.e074373.8","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28740","article-title":"Antiandrogens for the treatment of COVID-19 patients: A meta-analysis of randomized controlled trials","volume":"95","author":"Cheema","year":"2023","journal-title":"Journal of Medical Virology"},{"key":"2025101811465972000_14.4.e074373.9","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1111\/bcp.14629","article-title":"Challenges of drug development during the COVID-19 pandemic: key considerations for clinical trial designs","volume":"87","author":"Shi","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2025101811465972000_14.4.e074373.10","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab581","article-title":"Minimum manufacturing costs, national prices, and estimated global availability of new repurposed therapies for coronavirus disease 2019","volume":"9","author":"Wang","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025101811465972000_14.4.e074373.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219174"},{"key":"2025101811465972000_14.4.e074373.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025101811465972000_14.4.e074373.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025101811465972000_14.4.e074373.14","unstructured":"Higgins JPT , Thomas J , Chandler J , eds. Cochrane Handbook for Systematic Reviews of Interventions. 2nd edn. Hoboken, New Jersey: Wiley Blackwell, 2019."},{"key":"2025101811465972000_14.4.e074373.15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejim.2022.10.016","article-title":"Treatment with Colchicine in hospitalized patients affected by COVID-19: the COLVID-19 trial","volume":"107","author":"Perricone","year":"2023","journal-title":"Eur J Intern Med"},{"key":"2025101811465972000_14.4.e074373.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277790","article-title":"Efficacy of Colchicine in patients with moderate COVID-19: a double-blinded, randomized, placebo-controlled trial","volume":"17","author":"Rahman","year":"2022","journal-title":"PLoS ONE"},{"key":"2025101811465972000_14.4.e074373.17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ptr.7319","article-title":"Efficacy and safety of Colchicine treatment in patients with COVID-19: a prospective, multicenter, randomized clinical trial","volume":"36","author":"Pourdowlat","year":"2022","journal-title":"Phytother Res"},{"key":"2025101811465972000_14.4.e074373.18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11606-021-07203-8","article-title":"Colchicine is safe though ineffective in the treatment of severe COVID-19: a randomized clinical trial (COLCHIVID)","volume":"37","author":"Absal\u00f3n-Aguilar","year":"2022","journal-title":"J Gen Intern Med"},{"key":"2025101811465972000_14.4.e074373.19","article-title":"Randomized controlled trial of Colchicine add on to the standard therapy in moderate and severe corona virus disease-19 infection","volume":"77","author":"Gorial","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"2025101811465972000_14.4.e074373.20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001455","article-title":"Beneficial effects of Colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial","volume":"7","author":"Lopes","year":"2021","journal-title":"RMD Open"},{"key":"2025101811465972000_14.4.e074373.21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2213-2600(21)00222-8","article-title":"Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial","volume":"9","author":"Tardif","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025101811465972000_14.4.e074373.22","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2022.0083"},{"key":"2025101811465972000_14.4.e074373.23","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S2213-2600(21)00435-5","article-title":"Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"9","year":"2021","journal-title":"Lancet Respiratory Medicine"},{"key":"2025101811465972000_14.4.e074373.24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.41328","article-title":"Effect of Colchicine vs usual care alone on intubation and 28-day mortality in patients hospitalized with COVID-19: a randomized clinical trial","volume":"4","author":"Diaz","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025101811465972000_14.4.e074373.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101242","article-title":"Effectiveness of Rosuvastatin plus Colchicine, emtricitabine\/tenofovir and combinations thereof in hospitalized patients with COVID-19","volume":"43","author":"Gait\u00e1n-Duarte","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2025101811465972000_14.4.e074373.26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/injr.injr_264_21","article-title":"Effectiveness of Colchicine among patients with COVID-19 infection: a randomized, open-labeled, clinical trial","volume":"17","author":"Jalal","year":"2022","journal-title":"Indian J Rheumatol"},{"key":"2025101811465972000_14.4.e074373.27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/10815589221141815","article-title":"The effects of Colchicine on hospitalized COVID-19 patients: a randomized, double-blind, placebo-controlled clinical trial","volume":"71","author":"Kasiri","year":"2023","journal-title":"J Investig Med"},{"key":"2025101811465972000_14.4.e074373.28","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.2147\/IJGM.S329810","article-title":"Colchicine in recently hospitalized patients with COVID-19: a randomized controlled trial (COL-COVID)","volume":"14","author":"Pascual-Figal","year":"2021","journal-title":"Int J Gen Med"},{"key":"2025101811465972000_14.4.e074373.29","doi-asserted-by":"crossref","first-page":"2129006","DOI":"10.1155\/2021\/2129006","article-title":"Efficacy of Colchicine and Budesonide in improvement outcomes of patients with coronavirus infection 2019 in Damascus, Syria: a randomized control trial","volume":"2021","author":"Alsultan","year":"2021","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"2025101811465972000_14.4.e074373.30","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S2213-2600(22)00299-5","article-title":"Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial","volume":"10","author":"Eikelboom","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2025101811465972000_14.4.e074373.31","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2023.101070","article-title":"Effect of Colchicine and aspirin given together in patients with moderate COVID-19","volume":"32","author":"Sunil Naik","year":"2023","journal-title":"Contemp Clin Trials Commun"},{"key":"2025101811465972000_14.4.e074373.32","doi-asserted-by":"crossref","unstructured":"Pimenta Bonif\u00e1cio L , Ramacciotti E , Agati LB , et al . Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care on the treatment of patients hospitalized with moderate to critical COVID-19: a pilot randomized clinical trial (STRUCK: survival trial using Cyto kine inhibitors). SSRN Electron J 2022. doi:10.2139\/ssrn.4095747","DOI":"10.1590\/0037-8682-0565-2022"},{"key":"2025101811465972000_14.4.e074373.33","unstructured":"Mostafaie A . Colchicine plus phenolic Monoterpenes to treat COVID-19 [ClinicalTrials.gov]. n.d. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04392141"},{"key":"2025101811465972000_14.4.e074373.34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.31138\/mjr.33.2.232","article-title":"The impact of Colchicine on COVID-19 patients: a clinical trial study","volume":"33","author":"Salehzadeh","year":"2022","journal-title":"Mediterr J Rheumatol"},{"key":"2025101811465972000_14.4.e074373.35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13136","article-title":"Effect of Colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with Coronavirus disease 2019: the GRECCO-19 randomized clinical trial","volume":"3","author":"Deftereos","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025101811465972000_14.4.e074373.36","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1038\/s41598-022-13424-6","article-title":"Efficacy of short-course Colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trial","volume":"12","author":"Cecconi","year":"2022","journal-title":"Sci Rep"},{"key":"2025101811465972000_14.4.e074373.37","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S2213-2600(22)00298-3","article-title":"Colchicine and the combination of Rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial","volume":"10","author":"Eikelboom","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2025101811465972000_14.4.e074373.38","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.2174\/1381612827666211210142352","article-title":"A review of the rational and current evidence on Colchicine for COVID-19","volume":"28","author":"Ghaith","year":"2022","journal-title":"Curr Pharm Des"},{"key":"2025101811465972000_14.4.e074373.39","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1080\/07853890.2022.2096919","article-title":"Effect of Colchicine on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials","volume":"54","author":"Lan","year":"2022","journal-title":"Ann Med"},{"key":"2025101811465972000_14.4.e074373.40","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11092615","article-title":"Efficacy of Colchicine in the treatment of COVID-19 patients: a systematic review and meta-analysis","volume":"11","author":"Toro-Huamanchumo","year":"2022","journal-title":"J Clin Med"},{"key":"2025101811465972000_14.4.e074373.41","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1080\/03007995.2022.2100654","article-title":"The evidence from clinical trials on Colchicine and corticosteroids\u2019 effect on COVID-19: a systematic review and meta-analysis","volume":"38","author":"Bitar","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"2025101811465972000_14.4.e074373.42","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1097\/MJT.0000000000001511","article-title":"The effect of Colchicine on mortality, mechanical ventilation, and length of stay in patients with COVID-19 infection: an updated systematic review and meta-analysis of randomized clinical trials","volume":"29","author":"Romeo","year":"2022","journal-title":"Am J Ther"},{"key":"2025101811465972000_14.4.e074373.43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266245","article-title":"Safety and efficacy of Colchicine in COVID-19 patients: a systematic review and meta-analysis of randomized control trials","volume":"17","author":"Yasmin","year":"2022","journal-title":"PLoS One"},{"key":"2025101811465972000_14.4.e074373.44","doi-asserted-by":"crossref","first-page":"102395","DOI":"10.1016\/j.dsx.2022.102395","article-title":"Effect of Colchicine on mortality in patients with COVID-19 - A systematic review and meta-analysis","volume":"16","author":"Zein","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"2025101811465972000_14.4.e074373.45","doi-asserted-by":"crossref","DOI":"10.1177\/20587384211031763","article-title":"The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of Coronavirus disease 2019: meta-analysis","volume":"35","author":"Golpour","year":"2021","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2025101811465972000_14.4.e074373.46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/iid3.562","article-title":"The effect of Colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: a meta-analysis of randomized trials","volume":"10","author":"Kow","year":"2022","journal-title":"Immun Inflamm Dis"},{"key":"2025101811465972000_14.4.e074373.47","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20155","article-title":"Does Colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses","volume":"9","author":"Danjuma","year":"2023","journal-title":"Heliyon"},{"key":"2025101811465972000_14.4.e074373.48","unstructured":"Pollock M , Fernandes RM , Becker LA , et al . Chapter V: Overviews of reviews. In: Higgins JPT , Thomas J , Chandler J , eds. Cochrane Handbook for Systematic Reviews of Interventions. Wiley, 2019."},{"key":"2025101811465972000_14.4.e074373.49","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40121-020-00349-8","article-title":"Early treatment of COVID-19 disease: a missed opportunity","volume":"9","author":"Forrest","year":"2020","journal-title":"Infect Dis Ther"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-074373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:47:16Z","timestamp":1760813236000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-074373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,17]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/bmjopen-2023-074373"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-074373","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}